Isabelle Ray-Coquard Selected Research

Trabectedin

1/2022	Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study.
1/2022	Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
1/2021	Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin.
11/2018	Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial.
5/2018	Options for treating different soft tissue sarcoma subtypes.
10/2017	Trabectedin mechanism of action and platinum resistance: molecular rationale.
4/2015	Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.
3/2015	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
1/2015	Recent advances in understanding and managing leiomyosarcomas.
4/2014	Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Isabelle Ray-Coquard Research Topics

Disease

122	Neoplasms (Cancer) 04/2022 - 06/2002
71	Ovarian Neoplasms (Ovarian Cancer) 02/2022 - 03/2003
57	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 01/2004
30	Breast Neoplasms (Breast Cancer) 01/2022 - 10/2002
25	Carcinoma (Carcinomatosis) 02/2022 - 07/2006
16	Fatigue 01/2022 - 07/2009
16	Disease Progression 01/2022 - 05/2008
16	Neutropenia 01/2022 - 05/2006
13	Leiomyosarcoma 01/2022 - 08/2006
13	Hypertension (High Blood Pressure) 01/2021 - 07/2009
12	Anemia 01/2022 - 04/2003
12	Neoplasm Metastasis (Metastasis) 01/2022 - 08/2005
12	Ovarian Epithelial Carcinoma 11/2021 - 07/2014
12	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2020 - 08/2005
10	Thrombocytopenia (Thrombopenia) 01/2022 - 10/2008
9	Nausea 01/2022 - 07/2009
9	Lymphopenia (Lymphocytopenia) 01/2022 - 12/2004
7	Endometrial Neoplasms (Endometrial Cancer) 01/2022 - 12/2013
6	Hemangiosarcoma (Angiosarcoma) 01/2022 - 11/2008
6	Asthenia 01/2021 - 12/2016
6	Vomiting 11/2020 - 12/2012
6	Osteosarcoma (Osteogenic Sarcoma) 01/2020 - 08/2012
5	Febrile Neutropenia 01/2022 - 12/2004
5	Proteinuria 11/2020 - 07/2009
5	Ewing Sarcoma (Sarcoma, Ewing) 01/2020 - 10/2008
5	Stomatitis 01/2019 - 08/2012
5	Renal Insufficiency (Renal Failure) 01/2016 - 01/2009
4	Diarrhea 01/2022 - 08/2012
4	Liposarcoma 12/2016 - 01/2004
4	Synovial Sarcoma (Synovioma) 12/2016 - 01/2004
4	Carcinogenesis 01/2015 - 05/2004
3	Hemorrhage 01/2022 - 07/2014
3	Fallopian Tube Neoplasms 12/2021 - 02/2014
3	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 10/2021 - 01/2021
3	Colorectal Neoplasms (Colorectal Cancer) 04/2021 - 07/2007
3	Pathologic Complete Response 01/2021 - 08/2011

Drug/Important Bio-Agent (IBA)

50	PlatinumIBA 01/2022 - 03/2003
23	Paclitaxel (Taxol)FDA LinkGeneric 02/2022 - 03/2003
21	Bevacizumab (Avastin)FDA Link 01/2022 - 07/2007
21	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2021 - 01/2017
17	TrabectedinIBA 01/2022 - 10/2008
17	Imatinib Mesylate (Gleevec)FDA Link 01/2019 - 06/2002
16	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 08/2006
13	Pharmaceutical PreparationsIBA 02/2021 - 01/2009
12	olaparibIBA 01/2022 - 12/2016
12	Biomarkers (Surrogate Marker)IBA 02/2021 - 05/2011
11	Carboplatin (JM8)FDA LinkGeneric 02/2022 - 02/2004
10	Hormones (Hormone)IBA 01/2022 - 07/2011
10	liposomal doxorubicin (Doxil)FDA Link 11/2021 - 10/2010
9	rucaparibIBA 12/2021 - 01/2017
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 07/2007
9	pazopanib FDA Link 01/2020 - 07/2009
8	Ifosfamide FDA LinkGeneric 10/2020 - 08/2006
7	Immune Checkpoint InhibitorsIBA 04/2022 - 01/2019
7	Tyrosine Kinase InhibitorsIBA 01/2022 - 03/2007
7	Biological ProductsIBA 01/2022 - 07/2007
7	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2021 - 01/2017
7	Proteins (Proteins, Gene)FDA Link 04/2021 - 04/2008
7	taxaneIBA 01/2021 - 07/2004
6	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 02/2004
6	HematinicsIBA 02/2012 - 03/2008
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 03/2015
5	cabozantinibIBA 01/2022 - 10/2014
5	IronIBA 01/2022 - 03/2008
5	AnthracyclinesIBA 07/2021 - 03/2003
5	CreatinineIBA 01/2021 - 01/2009
5	Hemoglobins (Hemoglobin)IBA 01/2021 - 08/2005
5	Sunitinib (Sutent)FDA Link 01/2016 - 03/2007
5	Docetaxel (Taxotere)FDA Link 01/2015 - 02/2004
5	Sorafenib (BAY 43-9006)FDA Link 11/2014 - 01/2012
4	Epoetin Alfa (Epogen)FDA Link 01/2022 - 03/2008
4	regorafenibIBA 01/2022 - 01/2015
4	1-dodecylpyridoxal (PLD)IBA 11/2021 - 10/2010
4	Alanine Transaminase (SGPT)IBA 01/2021 - 10/2008
4	Gemcitabine FDA Link 01/2021 - 08/2006
4	AntigensIBA 04/2020 - 03/2009
4	Phosphotransferases (Kinase)IBA 01/2020 - 03/2007
4	ErbB Receptors (EGF Receptor)IBA 06/2016 - 08/2012
4	EnzymesIBA 10/2010 - 05/2004
3	nintedanibIBA 02/2022 - 01/2016
3	lenvatinibIBA 01/2022 - 01/2021
3	pembrolizumabIBA 01/2022 - 01/2021
3	Aromatase InhibitorsIBA 01/2022 - 08/2012
3	Poly Adenosine Diphosphate RiboseIBA 12/2021 - 01/2017
3	Etoposide (VP 16)FDA LinkGeneric 10/2021 - 01/2020
3	Messenger RNA (mRNA)IBA 04/2021 - 08/2011
3	Everolimus FDA Link 01/2021 - 08/2012
3	Angiogenesis InhibitorsIBA 01/2021 - 07/2007
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2007

Therapy/Procedure

84	Drug Therapy (Chemotherapy) 02/2022 - 01/2003
83	Therapeutics 02/2022 - 10/2002
8	Radiotherapy 01/2022 - 09/2005
6	Adjuvant Chemotherapy 01/2022 - 07/2004
6	Neoadjuvant Therapy 10/2020 - 05/2004
5	Immunotherapy 01/2022 - 01/2019
5	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 02/2004
4	Drug Tapering 01/2019 - 05/2006
3	Contraception (Birth Control) 01/2022 - 03/2018
3	Precision Medicine 01/2022 - 02/2021
3	Aftercare (After-Treatment) 10/2021 - 02/2008